https://pharmadevicenews.com/serp-01-gene-editing-results-support-phase-2-3-plans-for-inherited-lung-and-liver-disease/ PharmaDeviceNews en 2026-10-26T22:01:08+00:00 SERP-01 gene-editing results support Phase 2/3 plans for inherited lung and liver disease Boundless Bio, European Respiratory Society, Hannover Medical School, Renji Hospital, Serapha Bio, SERP-01, YolTech Therapeutics https://pharmadevicenews.com/wp-content/uploads/2026/10/Gene-editing-research-lab-e1793051707709.webp https://pharmadevicenews.com/orka-001-shows-strong-psoriasis-skin-clearance-results-as-pivotal-trials-approach-in-2027/ PharmaDeviceNews en 2026-10-26T21:24:08+00:00 ORKA-001 shows strong psoriasis skin-clearance results as pivotal trials approach in 2027 ORKA-001, ORKA-002, Oruka Therapeutics, University of Pennsylvania https://pharmadevicenews.com/wp-content/uploads/2026/10/Psoriasis-treatment-e1793049641354.webp https://pharmadevicenews.com/frontiers-fmc-376-triggered-responses-after-kras-inhibitor-failure-but-can-its-dual-state-mechanism-prevent-resistance/ PharmaDeviceNews en 2026-10-25T13:48:27+00:00 Frontier’s FMC-376 triggered responses after KRAS inhibitor failure, but can its dual-state mechanism prevent resistance? Adagrasib, European Society for Medical Oncology, FMC-376, Frontier Medicines, Keytruda, KRAS G12C, KRAZATI, LUMAKRAS, Marcelo Negrao, MD Anderson Cancer Center, pembrolizumab, PROSPER, sotorasib https://pharmadevicenews.com/wp-content/uploads/2026/06/Guardant360-CDx-FDA-approval-strengthens-the-liquid-biopsy-case-in-HER2-mutant-lung-cancer-e1781185177103.webp https://pharmadevicenews.com/beone-medicines-reports-new-phase-1-results-across-three-liver-and-lung-cancer-programmes/ PharmaDeviceNews en 2026-10-25T13:45:30+00:00 BeOne Medicines reports new Phase 1 results across three liver and lung cancer programmes BeOne Medicines, BG-C477, BGB-58067, BGB-B2033, European Society for Medical Oncology, KANDELA-302, Tevimbra, tislelizumab https://pharmadevicenews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-17-2026-09_15_56-AM-e1789616803290.webp https://pharmadevicenews.com/catalyms-visugromab-lifted-bladder-cancer-complete-responses-to-33-but-can-it-help-patients-avoid-surgery/ PharmaDeviceNews en 2026-10-25T07:03:16+00:00 CatalYm’s visugromab lifted bladder cancer complete responses to 33%, but can it help patients avoid surgery? Andrea Necchi, CatalYm, European Society for Medical Oncology, GDFATHER-NEO, IRCCS San Raffaele Hospital, Keytruda, Nature Medicine, nivolumab, Opdivo, PADCEV, visugromab https://pharmadevicenews.com/wp-content/uploads/2026/03/Signatera-MRD-data-at-ASCO-GU-raises-new-questions-about-who-really-needs-cystectomy-e1772373660512.webp https://pharmadevicenews.com/genmab-and-incyte-are-combining-three-attacks-on-kras-mutant-colorectal-cancer-but-can-they-overcome-egfr-resistance/ PharmaDeviceNews en 2026-10-25T06:58:10+00:00 Genmab and Incyte are combining three attacks on KRAS-mutant colorectal cancer, but can they overcome EGFR resistance? DAWN-303, EGFR, GEN1158, Genmab, INCB161734, Incyte, KRAS G12D, LGR5, petosemtamab, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/07/Verastem-doses-first-patient-in-TARGET-D-203-Phase-2-colorectal-cancer-trial-e1785297624822.webp https://pharmadevicenews.com/bayer-reports-58-lower-metastasis-or-death-risk-with-nubeqa-in-phase-3-prostate-cancer-trial/ PharmaDeviceNews en 2026-10-25T06:33:14+00:00 Bayer reports 58% lower metastasis or death risk with NUBEQA in Phase 3 prostate cancer trial ARAMIS, ARANOTE, ARASENS, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Bayer, Canadian Cancer Trials Group, darolutamide, DASL-HiCaP, European Society for Medical Oncology, NUBEQA, Orion Corporation, University of Sydney https://pharmadevicenews.com/wp-content/uploads/2026/06/AstraZenecas-Truqap-approval-raises-the-stakes-in-PTEN-deficient-prostate-cancer-care-e1781439693814.webp https://pharmadevicenews.com/astrazenecas-bladder-cancer-combination-cut-death-risk-by-42-but-can-it-compete-with-an-approved-rival-regimen/ PharmaDeviceNews en 2026-10-25T06:28:13+00:00 AstraZeneca’s bladder cancer combination cut death risk by 42%, but can it compete with an approved rival regimen? AstraZeneca, durvalumab, enfortumab vedotin, Imfinzi, KEYNOTE-905, Keytruda, Merck, New England Journal of Medicine, NIAGARA, PADCEV, United States Food and Drug Administration, VOLGA https://pharmadevicenews.com/wp-content/uploads/2026/05/Veracyte-enters-the-MRD-market-with-Medicare-backing-but-evidence-depth-will-decide-scale-e1778904337443.webp https://pharmadevicenews.com/astrazeneca-and-amgen-report-58-lower-death-risk-with-imfinzi-and-tarlatamab-in-small-cell-lung-cancer/ PharmaDeviceNews en 2026-10-25T04:43:04+00:00 AstraZeneca and Amgen report 58% lower death risk with IMFINZI and tarlatamab in small-cell lung cancer Amgen, AstraZeneca, CASPIAN, DeLLphi-304, DeLLphi-305, durvalumab, European Society for Medical Oncology, Imdelltra, Imfinzi, New England Journal of Medicine, tarlatamab https://pharmadevicenews.com/wp-content/uploads/2026/08/Lung-cancer-study-e1787082418957.webp https://pharmadevicenews.com/pfizers-new-vaccine-targets-25-pneumococcal-serotypes-but-can-it-outperform-prevnar-20/ PharmaDeviceNews en 2026-10-25T04:39:51+00:00 Pfizer’s new vaccine targets 25 pneumococcal serotypes, but can it outperform PREVNAR 20? Capvaxive, IDWeek 2026, Merck, PF-07872412, Pfizer, Prevnar 20, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/genmabs-rina-s-slashed-progression-risk-by-71-but-can-it-challenge-ovarian-cancer-treatment-standards/ PharmaDeviceNews en 2026-10-25T03:55:52+00:00 Genmab’s Rina-S slashed progression risk by 71%, but can it challenge ovarian cancer treatment standards? AbbVie, Corcept Therapeutics, ELAHERE, Genmab, Lifyorli, mirvetuximab soravtansine, ProfoundBio, RAINFOL-01, RAINFOL-02, Rina-S, Rinatabart Sesutecan, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/10/Ovarian-cancer-research-e1792867043247.webp https://pharmadevicenews.com/palleon-pharmaceuticals-reports-rapid-remissions-with-hlx79-e-602-in-phase-2-kidney-disease-trial/ PharmaDeviceNews en 2026-10-25T03:51:23+00:00 Palleon Pharmaceuticals reports rapid remissions with HLX79/E-602 in Phase 2 kidney disease trial American Society of Nephrology, Carolyn Bertozzi, efgitasialase alfa, HANLIKANG, HLX79/E-602, Palleon Pharmaceuticals, rituximab, Shanghai Henlius Biotech https://pharmadevicenews.com/wp-content/uploads/2026/07/Genentechs-Gazyva-gains-FDA-Priority-Review-after-Phase-III-MAJESTY-kidney-trial-e1784095258450.webp